These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15196715)

  • 1. GnRH analogs: depot versus short formulations.
    Dal Prato L; Borini A; Cattoli M; Bonu MA; Sereni E; Flamigni C
    Eur J Obstet Gynecol Reprod Biol; 2004 Jul; 115 Suppl 1():S40-3. PubMed ID: 15196715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study.
    Dal Prato L; Borini A; Coticchio G; Cattoli M; Flamigni C
    Hum Reprod; 2004 Oct; 19(10):2200-5. PubMed ID: 15271868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian stimulation concomitant with pituitary-ovarian axis suppression by different GnRH agonists.
    Insler V; Lunenfeld E; Potashnik G; Levy J
    Int J Fertil; 1991; 36(2):121-7. PubMed ID: 1674933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916).
    Safdarian L; Mohammadi FS; Alleyassin A; Aghahosseini M; Meysamie A; Rahimi E
    Hum Reprod; 2007 Sep; 22(9):2449-54. PubMed ID: 17635844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH antagonists.
    Coccia ME; Comparetto C; Bracco GL; Scarselli G
    Eur J Obstet Gynecol Reprod Biol; 2004 Jul; 115 Suppl 1():S44-56. PubMed ID: 15196716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
    Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
    Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
    Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Coasting and ovarian stimulation protocols in high-responder patients undergoing assisted conception].
    Merviel P; Claeys C; Héraud MH; Lourdel E; Lanta S; Barbier F; Nasreddine A
    Gynecol Obstet Fertil; 2005 Sep; 33(9):703-12. PubMed ID: 16129645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
    Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
    De Placido G; Mollo A; Clarizia R; Strina I; Conforti S; Alviggi C
    Fertil Steril; 2006 Jan; 85(1):247-50. PubMed ID: 16412769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of GnRH-antagonist to IVF-ET for patients with poor ovarian response].
    Wang B; Sun HX; Hu YL; Chen H; Zhang NY
    Zhonghua Nan Ke Xue; 2008 May; 14(5):423-6. PubMed ID: 18572861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot GnRH-agonist trigger for breast-cancer patient undergoing ovarian stimulation resulted in mature oocytes for cryopreservation: a case report.
    Cavagna M; Dzik A
    Reprod Biomed Online; 2011 Mar; 22(3):317-9. PubMed ID: 21273128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Controlled ovarian hyperstimulation (COH) and management of low-responder cases (HOO)].
    Vladimirov IaK
    Akush Ginekol (Sofiia); 2003; 42(3):23-6. PubMed ID: 12858487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.